Probiodrug, a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), has appointed Dr Michael Schaeffer to the position of Executive VP of Business and Strategy.
Dr Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Probiodrug.
CEO of Probiodrug, Dr Ulrich Dauer, said: "We are very pleased Michael has joined our team. His entrepreneurial skill sets and extensive experience in strategic business development for neurology projects across all stages of drug development will be invaluable in defining Probiodrug's business strategies."
"Additionally, he brings significant experience in advancing innovations in R&D alliance and CRO partnership management on a global scale. Together we look forward to tackling the next developmental stages of our lead candidate PQ912 as we prepare for our upcoming global Phase IIb studies."
Prior to joining Probiodrug, Dr Schaeffer was the Founder and Managing Director of biotech companies, CRELUX and SiREEN. Following the acquisition of CRELUX by WuXiAppTec in 2016, Dr Schaeffer was responsible for integrating CRELUX into the leading global CRO with more than 18,000 employees based in Shanghai.
Dr Schaeffer received his PhD in Molecular Biology from Ludwig-Maximilians-Universität in Munich, Germany.
"I was looking for an exciting business development role at a company that develops innovative drugs based on outstanding science and for indications with an extremely high medical need. Probiodrug exactly matches these requirements - I look forward to making a significant contribution as we are advancing our drug discovery programs" Dr. Michael Schaeffer added.